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Abstract
Purpose The safety of ovarian tissue autotransplantation
in oncology patients cannot be ensured, as current tumor-
detection methods compromise the ovarian tissue viability.
Although non-destructive methods (for instance near-in-
frared fluorescence imaging) can discriminate malignant
from healthy tissues while leaving the examined tissues
unaffected, they require specific cell-surface tumor mark-
ers. We determined which tumor markers are suitable tar-
gets for tumor-specific imaging to exclude the presence of
breast cancer cells in ovarian tissue.
Methods Immunohistochemistry was performed on for-
malin-fixed, paraffin-embedded specimens of ten ovaries
from premenopausal patients. Additionally, we screened a
tissue microarray containing tumor tissue cores from 24
breast cancer patients being eligible for ovarian tissue
cryopreservation. The following cell-surface tumor mark-
ers were tested: E-cadherin, EMA (epithelial membrane
antigen), Her2/neu (human epidermal growth factor
receptor type 2), avb6 integrin, EpCAM (epithelial cell
adhesion molecule), CEA (carcinoembryonic antigen), FR-
a (folate receptor-alpha), and uPAR (urokinase-type plas-
minogen activator receptor). For each tumor, the percent-
age of positive breast tumor cells was measured.
Results None of the ten ovaries were positive for any of
the markers tested. However, all markers (except CEA and
uPAR) were present on epithelial cells of inclusion cysts.
E-cadherin was present in the majority of breast tumors:
C90 % of tumor cells were positive for E-cadherin in 17
out of 24 tumors, and 100 % of tumor cells were positive in
5 out of 24 tumors.
Conclusions Of the markers tested, E-cadherin is the
most suitable marker for a tumor-specific probe in ovarian
tissue. Methods are required to distinguish inclusion cysts
from breast tumor cells.
Keywords Autotransplantation  Ovarian tissue  Breast
cancer  Tumor markers  Fertility preservation
Introduction
Premature ovarian failure is the most common long-term
major adverse effect in premenopausal women following
chemotherapy [1]. Because loss of fertility can significantly
decrease quality of life [2], considerable effort has been
devoted to offer these patients options for preserving their
fertility. These options currently include cryopreservation
of embryos and/or oocytes. Besides, autotransplantation of
pretreatment cryopreserved ovarian tissue is becoming
more prevalent and is considered predominantly feasible
for both prepubescent girls and women who cannot post-
pone adjuvant therapy [3–5].
Although autotransplantation of frozen-thawed ovarian
tissue has improved greatly in recent years [6, 7], its safety
is questionable for certain types of cancer at risk of ovarian
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involvement, as it remains uncertain whether the trans-
planted cortical ovarian strips contain metastatic cells. This
uncertainty arises from the highly damaging effects of
currently available tumor-detection methods (e.g., PCR,
immunohistochemistry) on tissue viability [8, 9]. There-
fore, traditional screening is performed using a limited
number of ovarian strips that are ultimately not trans-
planted. As a consequence of this approach, autotrans-
planting ovarian tissue involves the risk of reimplanting
diseased cells that can lead to cancer relapse in some
patients.
To safeguard the transfer of cortical ovarian tissue to the
patient, methods must be developed in which tumor cells
can be detected in ovarian autografts while preserving the
tissue’s reproductive function. Near-infrared fluorescence
(NIRF) imaging might be a suitable approach, as this
technique can safely distinguish malignant tissues from
non-malignant tissues in real time while leaving the tissues
viable [10]. A NIRF probe consists of a fluorophore that
emits light in the near-infrared spectrum
(k = 700–900 nm) conjugated to an antibody or peptide
with high affinity for a protein marker expressed selec-
tively at the cell surface of tumor cells [11, 12].
The first step towards developing tumor-specific imag-
ing is the identification of protein markers that are present
selectively at the cell surface of tumor cells, but absent on
cells within the normal ovarian cortex. Because breast
cancer is one of the primary indications for cryopreserva-
tion of ovarian tissue [13–16] and breast cancer metastases
in the ovaries have been reported with a prevalence ranging
from 13 to 47 % [8, 17], we examined a panel of cell-
surface markers known to be expressed by breast cancer
cells. This panel included human epidermal growth factor
receptor type 2 (Her2/neu) [18, 19], E-cadherin [20], and
carcinoembryonic antigen (CEA) [21]. In addition, we
tested several markers involved in tumor invasion and
migration, including epithelial cell adhesion molecule
(EpCAM) [22, 23], avb6 integrin [24], urokinase-type
plasminogen activator receptor (uPAR) [25, 26], and
epithelial membrane antigen (EMA, also known as MUC1)
[27, 28]. Lastly, we included folate receptor-alpha (FR-a),
which is expressed in several tumor types but not in normal
ovarian tissue [29]. We excluded cytokeratin CAM 5.2,
gross cystic disease fluid protein-15 (GCDFP15), Wilms’
tumor antigen-1 (WT1), mammaglobin 1, and cytokeratin 7
(CK-7), which were used previously by Sa´nchez-Serrano
et al. [30] and Rosendahl et al. [31], as these proteins are
not expressed at the cell surface and therefore not suit-
able as a target for tumor-specific imaging.
In this study, we measured the expression levels of the
above-mentioned markers in breast cancer cells obtained
from patients who were potentially eligible for cryop-
reservation of ovarian tissue. In addition, we compared





Formalin-fixed, paraffin-embedded (FFPE) specimens of
control ovaries obtained from premenopausal patients who
underwent a unilateral or bilateral oophorectomy in
2001–2012 were selected from the archives of the
Department of Pathology at the Leiden University Medical
Center (LUMC). The clinical data were extracted from the
patients’ medical records. Indications for surgery included
suspected malignancy in the contralateral ovary, early-
stage uterine sarcoma, endometrial carcinoma, squamous
cell carcinoma of the cervix, or enlarged ovary during
pregnancy. BRCA mutation carriers and women with
unknown BRCA mutation status were excluded. Patients
who used a gonadotropin-releasing hormone (GnRH)
agonist or oral contraceptives prior to oophorectomy were
excluded to ensure that only functionally active ovaries
were studied. A pathologist specialized in gynecology
confirmed the absence of overt abnormalities in the ovaries
by reviewing hematoxylin-and-eosin-stained sections. A
total of ten control ovaries from ten different patients were
included.
Breast cancer tissue
Breast tumor samples were collected from 24 patients who
were potentially eligible for cryopreservation of their
ovarian tissue based on the inclusion criteria established by
the Dutch Network of Fertility Preservation [32]. All
women were B35 years of age and were diagnosed with
invasive breast carcinoma for which they were treated
surgically at the LUMC in 1997–2009. The following data
were obtained from the medical records: age at the time the
tissue was obtained, TNM (tumor/node/metastasis) stage,
histological subtype, Scarff-Bloom-Richardson (SBR)
grade, and expression of the estrogen and progesterone
receptors. All patients were eligible for adjuvant
chemotherapy based on the current protocols, and none was
diagnosed with distant metastases.
Immunohistochemistry
Immunohistochemistry was performed on 4-lm thick
FFPE sections of control ovaries and 4-lm thick slices of a
tissue microarray (TMA) containing invasive breast tumor
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cores. To generate the TMA, tissue biopsies measuring
1.0 mm in diameter were taken in triplicate from repre-
sentative regions of the FFPE tumor samples and arrayed
into a new recipient paraffin block using TMA Master
(3DHistech, Hungary). The tissue sections were deparaf-
finized in xylene, rehydrated in a stepwise series of graded
alcohol solutions, and rinsed in distilled water. After
blocking endogenous peroxidase activity with 0.3 %
hydrogen peroxide for 20 min, heat-induced antigen
retrieval was performed by placing the slides in EnVision
Flex Target Retrieval Solution high pH/low pH in PT Link
(Dako, Denmark). EpCAM and avb6 integrin epitopes
were unmasked by 30-min incubation with 0.125 % trypsin
and 0.4 % pepsin, respectively, at 37 C. The sections were
incubated overnight in a humidified chamber at room
temperature with primary antibodies against Her2/neu
(ERBB2, rabbit polyclonal, Dako), E-cadherin (NCH38,
mouse monoclonal, Dako), EpCAM (323/A3, mouse
monoclonal, provided by the Department of Pathology,
LUMC, the Netherlands), CEA (A0115, rabbit polyclonal,
Dako), avb6 integrin (6.2A1, mouse monoclonal, Cell
Essentials), uPAR (ATN615, mouse monoclonal, kindly
provided by Prof. A.P. Mazar, Northwestern University,
Evanston, IL), or EMA (E29, mouse monoclonal, Dako);
all primary antibodies were used at their predetermined
optimal dilution. Some sections were incubated with an
antibody against FR-a (26B3.F2, mouse monoclonal,
Biocare Medical) for 60 min in accordance with the man-
ufacturer’s instructions. After incubation with the primary
antibody, the sections were rinsed with PBS, incubated
with secondary antibody (anti-mouse or anti-rabbit EnVi-
sion; Dako) for 30 min, and visualized using liquid
DAB?substrate buffer (Dako). The sections were coun-
terstained with Mayer’s hematoxylin solution, dehydrated,
and permanently mounted with Pertex (Leica Microsys-
tems, Germany). For each immunostain, a positive control
expressing the antigen of interest was included. The pri-
mary antibody was omitted as a negative control.
Image capture and quantification
of immunoreactivity
The immunostained slides were scanned using a Pannoramic
MIDI digital slide scanner (3DHistech, Hungary). Immuno-
histochemical staining of the ovary sections was evaluated by
the primary researcher (I.P.) and an experienced pathologist
specialized in gynecology (V.S.). In each breast tumor tissue
core sample, the percentage of breast tumor cells and the
percentage of positively stained membranes among the
malignant cells were scored by two independent observers
(I.P. and R.V.). In the event of a major discrepancy, the
observers reached consensus regarding a final score. The
tumor cell membranes were considered positive if they
showed immunoreactivity of any intensity. A weighted scor-
ing method based on the size of the tumor area in each tumor
core was used to calculate the percentage of positive mem-
brane-stained tumor cells in each sample.
Statistical analysis
Statistical analysis was performed using SPSS version 20.0
(IBM, Armonk, NY). Inter-observer agreement was cal-
culated using the Pearson correlation coefficient. The
suitability threshold for the putative NIRF probe targets




A histological analysis showed that all ovaries contained
follicles. The cortex of each ovary was negative for
immunohistochemical staining by all markers tested. In
contrast, all markers (except CEA and uPAR) were
detected at the plasma membrane of epithelial cells in
inclusion cysts (Fig. 1a, b). These inclusion cysts were
present in five of the ten ovaries. In addition, E-cadherin
was expressed at moderate levels in the granulosa cells of
primary follicles (Fig. 2).
Breast cancer tissue
The median age at the time of diagnosis was 32 years (range
21–35 years) for the 24 patients included in the TMA
analysis. Twenty-three patients were diagnosed with ductal
breast cancer, and the remaining patient was diagnosed with
lobular breast carcinoma. The characteristics of these 24
patients and their tumors are summarized in Table 1.
Expression of investigated markers
Microscopic quantification of marker levels was possible in
all breast tumor samples. Strong correlation was obtained
between the scoring results obtained by the two observers;
the median R2 was 0.746 (range 0.626–0.818). E-cadherin,
EMA, Her2/neu, CEA, and uPAR staining was positive in
both the plasma membrane and cytoplasm of the breast
cancer cells, whereas avb6 integrin, EpCAM, and FR-a
staining was confined to the membrane. In addition, uPAR
staining was observed in stromal cells surrounding the
tumor cells (Fig. 3).
The median (range) percentage of positive tumor cells
was 94 % (5–100) for E-cadherin, 78 % (13–100) for
EMA, 61 % (11–100) for Her2/neu, 56 % (2–100) for
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avb6 integrin, 54 % (0–100) for EpCAM, 23 % (0–100)
for CEA, and 3 % (0–100) for FR-a. uPAR was expressed
in extremely few tumor and stromal cells, 0 % (0–11) and
0 % (0–14), respectively (Table 2).
Potential targets for imaging
Given that breast cancer is relatively heterogeneous and
that the expression of antigens varied among the tumors
Fig. 1 a Immunohistochemical expression of E-cadherin, EMA,
Her2/neu and avb6 integrin in ovarian cortices and inclusion cysts.
Stromal cells stained negative, but E-cadherin, EMA, Her2/neu and
avb6 integrin showed expression at the epithelial cells of inclusion
cysts. Scale bars in the upper panel represent 100 lm and scale bars
in the lower panel represent 200 lm. b Immunohistochemical
expression of EpCAM, CEA, FR-a and uPAR in ovarian cortices
and inclusion cysts. Stromal cells stained negative, but EpCAM and
FR-a showed expression at the epithelial cells of inclusion cysts.
Scale bars in the upper panel represent 100 lm and scale bars in the
lower panel represent 200 lm
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examined (Table 2), targeting one membrane protein
would likely be insufficient for detecting all possible
tumor cells in each patient. Therefore, to facilitate the
selection of possible targets, we used suitability thresh-
olds set at 80, 90, and 100 %, corresponding to the
percentage of tumor cells that expressed the various
antigens.
Figure 4 summarizes the suitability of each tumor
marker for detecting invasive tumor cells in the 24 patients
who were diagnosed with breast cancer. Based on this
analysis, E-cadherin was identified as the most suit-
able marker for detecting breast cancer cells; specifically,
E-cadherin was present in 100 % of cells in five tumors,
and this marker was present in C90 % of cells in 17
tumors. The seven tumors with \90 % positivity for
E-cadherin were positive for the markers EMA (1 tumor;
100 % of cells detected), avb6 integrin (3 tumors;
78–93 % of cells detected), EpCAM (1 tumor; 81 % of
cells detected), E-cadherin (1 tumor; 80 % of cells detec-
ted), and Her2neu (1 tumor; 76 % of cells detected). Two
tumors had\80 % positivity for all of the markers tested
(Table 2). In these two tumors, 76 and 78 % of the tumor
cells were detected by the markers, corresponding to a
maximum of 24 and 22 % of undetected malignant cells,
respectively.
Comment
Here, we identified several proteins that could potentially
serve as a suitable target for detecting breast cancer cells
within ovarian autografts. One clear application for these
markers is the use of NIRF imaging, a technique that can
differentiate malignant tissues from non-malignant tissues
without reducing the tissue’s viability [10, 33–35].
Designing a NIRF probe directed against E-cadherin shows
particular promise, as E-cadherin was expressed by the
majority (94 %) of invasive breast tumor cells and was
absent on the surface of normal ovarian cells. However, a
combination of tumor-selective probes will likely be nee-
ded to detect all tumor cells. Based on our results, a
combination of probes against E-cadherin, EMA and Her2/
neu seems suitable.
Metastatic spread requires the local invasion of the
surrounding host tissue by cells that originated from the
primary tumor, followed by intravasation in blood and
lymphatic vessels, ultimately leading to the dissemination
of tumor cells [36]. E-cadherin and EpCAM mediate cell–
cell adhesion, and the downregulation or loss-of-function
of these proteins enables cells to escape from solid tumors
[19]. E-cadherin and/or EpCAM are not necessarily
expressed in all tumor cells; therefore, metastatic tumor
cells might not be detected in some tissues. Furthermore,
the majority of metastatic lobular breast cancer cells, which
Fig. 2 Immunohistochemical staining of E-cadherin showed moder-
ate expression in the granulosa cells of primary follicles in the ovarian
cortex (arrows). Scale bar represents 200 lm
Table 1 Clinicopathologic characteristics in premenopausal patients
with primary invasive breast cancer
Characteristic N = 24
Age at diagnosis, years—median (range) 32.0 (21–35)
Tumor size, mm—median (range) 20.5 (10–45)





Lymph node involvement, no. (%)
pN0 13 (54.2)
pN1 11 (45.8)




Histological subtype, no. (%)
Ductal 23 (95.8)
Lobular 1 (4.2)
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lack E-cadherin expression, will not be detected using a
specific anti-E-cadherin probe, even though lobular breast
cancer cells are more likely to invade ovarian tissue
compared to cells derived from ductal carcinomas [37, 38].
As mentioned above, we considered tumor cell mem-
branes positive if they showed immunoreactivity of any
intensity. As a result, some tumor cells might be more
positive than others for the investigated markers. Yet, for
Fig. 3 Immunohistochemical expression of E-cadherin, EMA, Her2/neu, avb6 integrin, EpCAM, CEA, FR-a and uPAR in invasive breast
cancer. uPAR was barely expressed in stromal cells surrounding the tumor (arrows). Scale bars represent 100 lm
Table 2 The percentage of tumor cells in each tumor showing positive expression for the investigated tumor markers
Tumor nr. E-cadherin EMA Her2neu αvβ6 integrin EpCAM CEA FR-α uPAR tumor a uPAR stroma a
1 100 90 34 11 95 0 0 3 0 100% of tumor cells 
2 93 91 63 54 40 5 6 0 0 90-99% of tumor cells
3 90 84 100 98 92 100 3 0 0 80-89% tumor cells
4 58 35 76 31 40 24 0 0 0
5 94 38 60 85 71 81 98 0 0
6 80 69 35 50 22 18 7 0 0
7 97 82 68 9 100 4 0 0 0
8 5 52 50 90 35 74 52 0 3
9 94 100 78 95 0 15 25 0 0
10 100 100 88 71 2 13 0 0 0
11 88 78 47 93 67 0 33 6 14
12 95 77 77 24 83 20 0 0 0
13 50 74 40 2 81 31 0 0 0
14 94 100 96 90 10 2 3 0 0
15 100 37 13 100 100 95 80 11 8
16 91 89 100 40 98 76 0 0 0
17 100 38 100 41 100 28 0 0 0
18 54 50 48 78 0 27 52 10 0
19 63 100 96 93 8 67 0 0 0
20 95 13 34 43 94 77 3 10 7
21 100 95 100 62 13 21 0 0 2
22 94 77 45 58 21 0 1 3 0
23 92 94 55 35 42 74 100 7 0
24 97 65 11 31 82 4 5 0 0
Median 94 78 61 56 54 23 3 0 0
a uPAR expression was subdivided into tumor and stromal expression. 
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NIRF imaging, the staining intensity is less important as
long as a significant tumor-to-background-ratio can be
achieved.
None of the premenopausal ovaries in our cohort had
positive staining in either the stromal cells or the ovarian
surface epithelium. However, all markers (except CEA and
uPAR) were expressed on epithelial cells in inclusion cysts.
Consequently, conjugating antibodies against these mark-
ers to a NIR fluorophore will illuminate invasive breast
cancer cells in the ovary, as well as inclusion cysts.
Because inclusion cysts might differ from metastatic breast
cancer cells with respect to their fluorescent configuration,
it might be possible to distinguish between these structures.
The same strategy might be used to distinguish granulosa
cells in primary follicles from metastatic breast cancer cells
that express E-cadherin. In addition, full-field optical
coherence tomography (FF-OCT), a non-invasive imaging
technique that mimics conventional histopathology, might
be very useful. In the field of dermatological oncology, FF-
OCT has already been proven capable of visualizing
sebaceous glands and adipose tissue surrounding hair fol-
licles as well as small malignant skin tumors [39]. On high
magnification, fine architectural details on the subcellular
level can be recognized. Therefore, it is expected that FF-
OCT will also be able to distinguish inclusion cysts from
metastatic tumor cells in ovarian tissue.
One strength of our study is that we examined the
expression of tumor markers in tumor tissues obtained from
young breast cancer patients who met the criteria for
ovarian tissue cryopreservation. Moreover, only biologi-
cally active ovaries were analyzed, giving the results
clinical relevance, as ovarian tissue is generally cryopre-
served before ovarian failure has occurred.
On the other hand, this study has some limitations that
merit discussion. First, a relatively small sample size was
examined. However, normal ovarian tissue from pre-
menopausal patients is not readily available. We excluded
ovaries that were removed due to the presence of a BRCA
gene mutation, as such samples could contain primary
ovarian tumor cells [40], that express the markers investi-
gated in this study. To be certain, we also excluded ovaries
from breast cancer patients with unknown mutation status.
At the LUMC, normal ovarian tissue from premenopausal
breast cancer patients was exclusively available from
BRCA mutation carriers or women with unknown mutation
status. As a consequence, ovaries from breast cancer
patients were not included in this study. Malignant cells
may also be present in ovaries that were removed due to
endometrial carcinoma, uterine sarcoma, cervical squa-
mous cell carcinoma, or contralateral ovarian carcinoma;
however, the risk of false-positive results was relatively
low in our cohort, as all primary tumors were diagnosed at
an early stage and the lymph nodes in these patients were
clear. Second, the expression of the markers was evaluated
on primary invasive breast tumors, since a substantial
cohort consisting of ovarian tissues containing breast can-
cer metastases is scarce. Finally, we examined the
expression of tumor markers in relatively small tumor
cores using a TMA approach. Yet, the TMA technique is
considered an accurate method for examining protein
expression in breast cancer tissues [41].
Recently, the intraoperative use of tumor-targeted fluo-
rescent imaging yielded a high tumor identification rate and
enabled the surgeon to detect metastases that could not be
detected by visual observation [42]. For our purpose,
tumor-specific NIRF probes could be administered intra-
venously prior to oophorectomy, after which the removed
ovary is dissected into cortical ovarian strips. Detailed
fluorescent images could then be obtained using multi-
photon microscopy, which provides an inherent submicron
spatial resolution that allows revelation of subcellular
details with reduced phototoxicity and photobleaching [43,
44]. Because the NIRF signal lies beyond the red end of the
visible spectrum, the signal has enhanced tissue penetra-
tion, enabling the identification of fluorescently labeled
tumor cells that are located deep within the tissue. More-
over, the low autofluorescence of the tissue at the emission
wavelength of the probe provides a high tumor-to-back-
ground ratio [45]. Because of these features and the fact
that cortical ovarian fragments can be imaged from both
the upper and lower side, thereby increasing the imaging
depth even further, NIRF imaging is a promising technique
for detecting tumor cells in cortical ovarian strips up to
2 mm in thickness.
Fig. 4 Suitability of tumor markers to use as a target for the detection
of tumor cells in premenopausal women with invasive breast cancer
(n = 24). Columns represent the number of tumors in which at least
80, at least 90 or 100 % of the tumor cells showed expression of the
tumor markers. For uPAR, stromal cell expression is also shown
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In conclusion, we report the identification of tumor
markers that may serve as a target for detecting breast
cancer cells in ovarian tissue using robust imaging tech-
niques such as NIRF imaging. Based on our analysis,
E-cadherin is likely the most suitable target for designing a
tumor-specific probe. Further research will focus on
examining the expression of these markers on breast cancer
metastases in ovaries, refining methods to distinguish
breast cancer cells from ovarian inclusion cysts, and
examining the clinical feasibility of applying NIRF imag-
ing to the field of fertility preservation.
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